RTADM: Comparative Study of the Efficacy and Risk Profile of Two Animal-derived Acellular Dermal Matrices in Patients Undergoing Mastectomy, Radiotherapy and Implant-based Reconstruction

Sponsor
European Institute of Oncology (Other)
Overall Status
Completed
CT.gov ID
NCT06139588
Collaborator
(none)
146
1
76.4
1.9

Study Details

Study Description

Brief Summary

The goal of this retrospective observational trial is to compare two different devices, used in implant-based breast reconstruction, called acellular dermal matrices, which are a sort of collagen patch that integrates with the tissues of the patient and helps in contrasting the collateral effects of radiotherapy (capsular contracture, implant loss)

The main questions the study aims to answer are:
  • is one of the two matrices better than the other? (better results with fewer complications)

  • is there a group of patients who benefit more than another from the use of this type of devices?

  • is there an adm which works better in one specific subgroup of patients? Participants have undergone mastectomy, radiotherapy and implant reconstruction with the aid of two different kinds of acellular dermal matrices.

Researchers will compare patients who receive the porcine-derived adm and the patients who receive bovine-derived adm to see if there is a difference in terms of capsular contracture reduction, aestethic result and complications.

Condition or Disease Intervention/Treatment Phase
  • Device: acellular dermal matrix implant for breast reconstruction

Detailed Description

Radiotherapy is highly effective in breast cancer treatment, yet it impairs satisfactory implant-based reconstruction, due to high rates of capsular contracture and implant loss. This said, a fervent investigtion exists upon solutions that can make implant-based reconstruction safer and aesthetically satisfying, including the use of acellular dermal matrices. We retrospectively want to analyze our ADM-assisted post-RT implant-based breast reconstructions comparing two different matrices (porcine and bovine), when autologous reconstruction was contraindicated, to assess eventual differences in efficacy and risk profile of the devices. We want to further stratify the population in 4 groups based on clinical presentation to assess if there was a group where ADMs proves to perform better (Group A - previous quadrantectomy, Group B - previous mastectomy and expander reconstruction, Group C - previous mastectomy and implant reconstruction, Group D - prior quadrantectomy followed by mastectomy and implant reconstruction).

Study Design

Study Type:
Observational
Actual Enrollment :
146 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Comparative Study of the Efficacy and Risk Profile of Two Animal-derived Acellular Dermal Matrices in Patients Undergoing Mastectomy, Radiotherapy and Implant-based Reconstruction
Actual Study Start Date :
Jun 1, 2017
Actual Primary Completion Date :
Dec 31, 2022
Actual Study Completion Date :
Oct 13, 2023

Arms and Interventions

Arm Intervention/Treatment
POST QUART NATIVE

Native adm used in the setting of mastectomy and implant reconstruction after QUART

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

POST QUART VERITAS

Veritas adm used in the setting of mastectomy and implant reconstruction after QUART

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

POST EXPANDER NATIVE

Native adm used in the setting of expander removal and implant positioning after mastectomy + RT

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

POST EXPANDER VERITAS

Veritas adm used in the setting of expander removal and implant positioning after mastectomy + RT

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

IMPLANT EXCHANGE NATIVE

Native adm used in the setting of implant exchange after mastectomy + RT

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

IMPLANT EXCHANGE VERITAS

Veritas adm used in the setting of implant exchange after mastectomy + RT

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

IMPANT EXCHANGE AFTER QUART NATIVE

Native adm used in the setting of implant exchange after QUART+ Mastectomy and implant reconstruction

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

IMPLANT EXCHANGE AFTER QUART VERITAS

Veritas adm used in the setting of implant exchange after QUART+ Mastectomy and implant reconstruction

Device: acellular dermal matrix implant for breast reconstruction
acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Outcome Measures

Primary Outcome Measures

  1. ADM efficacy and risk profile comparison [60 months]

    Does one dermal matrix perform better than the other in terms of efficacy and complication rates?

Secondary Outcome Measures

  1. Best clinical setting for ADM use [60 months]

    Is there a subgroup of patient where the use of ADM proves more beneficial than others?

Other Outcome Measures

  1. ADM comparison in each clinical setting group [60 months]

    Is there a type of dermal matrix that performs better than the other in a specific subgroup of patients?

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • at least 6 months follow up

  • breast reconstruction with implant + acellular dermal matrix after mastectomy and radiotherapy

Exclusion Criteria:
  • mastectomy flap <1 cm

  • autoimmune disease

  • prolonged use of corticosteroids

Contacts and Locations

Locations

Site City State Country Postal Code
1 European Institute of Oncology Milan Lombardy Italy 20141

Sponsors and Collaborators

  • European Institute of Oncology

Investigators

  • Principal Investigator: Andrea Vittorio Emanuele Lisa, MD, Istituto Europeo di Oncologia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
European Institute of Oncology
ClinicalTrials.gov Identifier:
NCT06139588
Other Study ID Numbers:
  • UID4321
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by European Institute of Oncology
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2023